PANDEMIC PULSE

Facebook
Twitter
LinkedIn
Print

FDA Authorizes Second mRNA Booster Dose for Adults Over 50 and Immunocompromised Individuals

On March 29, 2022, the U.S. Food and Drug Administration (FDA) authorized a second booster dose of either the Pfizer COVID-19 vaccine (marketed as Comirnaty) or the Moderna COVID-19 vaccine (marketed as Spikevax) for adults 50 years of age or older and individuals with compromised immune systems. The updated authorizations for these vaccines are as follows:

  • Adults 50 years of age and older can receive a second booster dose at least four months after the first booster dose was administered;
  • Individuals 12 years of age and older who have a compromised immune system can receive a second booster dose of Comirnaty at least four months after the first booster dose was administered; and
  • Individuals 18 years of age and older who have a compromised immune system can receive a second booster dose of Spikevax at least four months after the first booster dose was administered.

To support the agency’s decision, the FDA cited data from Israel that showed a 78 percent reduced mortality rate for older adults who received a second booster dose of an mRNA vaccine compared to adults who received just one booster dose. If you have not yet been vaccinated against COVID-19, Pandemic Patients recommends that you consult with your health care provider to discuss getting vaccinated as soon as possible. If you are unsure about your eligibility for the COVID-19 vaccine, review our Vaccine Eligibility Guide to learn more.

FDA Grants EUA to Novavax COVID-19 Vaccine

On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax’s COVID-19 vaccine. The FDA’s authorization of this vaccine provides an additional option for individuals who wish to get vaccinated against COVID-19.

Continue Reading...

FDA Authorizes Pfizer and Moderna COVID-19 Vaccines for Children

On June 17, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorizations (EUA) for the Pfizer and Moderna vaccines (marketed as Comirnaty and Spikevax) to allow children as young as six months to get vaccinated against COVID-19. In making this decision, the FDA concluded that the vaccines are safe and effective for use in this population and that the benefits of vaccination outweigh the potential risks.

Continue Reading...

FDA Authorizes First Vaccine Booster for Children 5-11

On May 17, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (marketed as Comirnaty) to authorize the use of a single booster dose for children between the ages of five and eleven. The FDA authorized the administration of this booster at least five months after the completion of the primary vaccination series with the same vaccine.

Continue Reading...

DONATE NOW to support Pandemic Patients

Bivalent COVID-19 vaccine boosters are now available.

Get your booster today!

"Pandemic Patients relies on donations from the public to operate. With a tax-deductible gift, you can partner with us to help support patients and survivors of COVID-19. Can you make a $10 donation to Pandemic Patients today?"